Aviso: Este site agrega dados públicos oficiais da FDA, ClinicalTrials.gov, PubMed e SEC EDGAR apenas para referência geral. Não constitui aconselhamento médico, diagnóstico, recomendação de tratamento ou aconselhamento de investimento.

PubMed

Generating comparative evidence on new drugs and devices before approval.

PMID: 32199486 ·

H, u, s, e, y, i, n, , N, a, c, i, ;, , M, a, x, i, m, i, l, i, a, n, , S, a, l, c, h, e, r, -, K, o, n, r, a, d, ;, , A, a, r, o, n, , S, , K, e, s, s, e, l, h, e, i, m, ;, , B, e, a, t, e, , W, i, e, s, e, l, e, r, ;, , L, i, s, e, , R, o, c, h, a, i, x, ;, , R, i, t, a, , F, , R, e, d, b, e, r, g, ;, , G, e, o, r, g, i, a, , S, a, l, a, n, t, i, ;, , E, m, i, l, y, , J, a, c, k, s, o, n, ;, , S, a, r, a, h, , G, a, r, n, e, r, ;, , T, , S, c, o, t, t, , S, t, r, o, u, p, ;, , A, n, d, r, e, a, , C, i, p, r, i, a, n, i

RevistaLancet (London, England)
Ano
PMID32199486

Resumo

Fewer than half of new drugs have data on their comparative benefits and harms against existing treatment options at the time of regulatory approval in Europe and the USA. Even when active-comparator trials exist, they might not produce meaningful data to inform decisions in clinical practice and health policy. The uncertainty associated with the paucity of well designed active-comparator trials has been compounded by legal and regulatory changes in Europe and the USA that have created a complex

Fonte oficial

Ver no PubMed →

Dados provenientes do PubMed / NCBI. Para consultar o texto integral e as informações mais recentes, recorra sempre ao registo oficial.

↑